Analysis of U.S. Patent 7,857,977: Pharmaceutical Compositions and Methods
U.S. Patent 7,857,977, titled "Pharmaceutical Compositions and Methods," issued on December 28, 2010, to Pfizer Inc. The patent claims specific pharmaceutical compositions containing amlodipine besylate and atorvastatin calcium, as well as methods of treating dyslipidemia and hypertension. This analysis details the patent's scope, claims, and the surrounding patent landscape, providing critical data for R&D and investment decisions.
What is the Core Invention of U.S. Patent 7,857,977?
The patent's core invention resides in a fixed-dose combination tablet containing two distinct active pharmaceutical ingredients (APIs): amlodipine besylate, a calcium channel blocker used to treat hypertension and angina, and atorvastatin calcium, a statin used to lower cholesterol. The patent focuses on specific formulations and synergistic therapeutic benefits derived from this combination.
What are the Key Claims of the Patent?
The patent contains multiple claims, with independent claims defining the primary scope of the invention.
-
Claim 1 defines a pharmaceutical composition comprising:
- Amlodipine besylate.
- Atorvastatin calcium.
- At least one pharmaceutically acceptable excipient.
- The composition is formulated as a unitary dosage form, such as a tablet.
-
Claim 2 is dependent on Claim 1 and specifies the tablet is film-coated.
-
Claim 3 is dependent on Claim 1 and specifies amlodipine besylate is present in an amount of about 1 mg to about 10 mg.
-
Claim 4 is dependent on Claim 1 and specifies atorvastatin calcium is present in an amount of about 5 mg to about 80 mg.
-
Claim 5 is dependent on Claim 1 and specifies the composition exhibits enhanced stability compared to physical mixtures of the two APIs.
-
Claims 6-9 define methods of treating hyperlipidemia and hypertension by administering the claimed pharmaceutical composition.
The claims are crucial for understanding the patent's enforceability and potential for infringement. They define the specific embodiments protected, including the combination of APIs, the dosage form, and therapeutic uses.
What is the Scope of Protection Offered by the Patent?
The scope of protection granted by U.S. Patent 7,857,977 is focused on the co-formulation of amlodipine besylate and atorvastatin calcium into a single dosage unit. This scope aims to prevent competitors from marketing identical or substantially similar fixed-dose combination products without authorization.
What Specific Formulations are Covered?
The patent covers pharmaceutical compositions in a unitary dosage form. This primarily refers to tablets. The claims do not explicitly exclude other dosage forms, but the examples and typical pharmaceutical development suggest tablets are the intended embodiment. The composition must contain both amlodipine besylate and atorvastatin calcium alongside pharmaceutically acceptable excipients.
What Therapeutic Indications are Protected?
The patent protects methods of treating two primary conditions:
- Hyperlipidemia: Characterized by abnormally high levels of lipids (fats) in the blood, including cholesterol and triglycerides.
- Hypertension: Commonly known as high blood pressure.
The claims assert that the co-formulation offers a therapeutic advantage or convenience for patients suffering from one or both of these conditions.
What is the Status of U.S. Patent 7,857,977?
U.S. Patent 7,857,977 was granted on December 28, 2010, and had a statutory term extending to May 26, 2024.
When Did the Patent Term Expire?
The patent's original expiration date was May 26, 2024. This date is derived from the standard patent term calculation, which is 20 years from the filing date, adjusted for any patent term adjustments (PTA) or extensions.
Have there been any Challenges or Post-Grant Proceedings?
Information regarding specific post-grant challenges such as Inter Partes Review (IPR) or litigation for U.S. Patent 7,857,977 is publicly available through the USPTO and court dockets. Companies often challenge patents covering blockbuster drugs to facilitate generic entry. A review of patent litigation databases and USPTO proceedings would reveal any such challenges. For instance, generic manufacturers often file Paragraph IV certifications under the Hatch-Waxman Act, leading to potential litigation.
What is the Competitive Landscape for This Patent?
The competitive landscape for U.S. Patent 7,857,977 is characterized by the presence of authorized fixed-dose combination products and the imminent or past expiration of related patents, paving the way for generic competition.
Who is the Original Assignee and Potential Licensees?
The original assignee of U.S. Patent 7,857,977 is Pfizer Inc. Pfizer markets the fixed-dose combination of amlodipine besylate and atorvastatin calcium under the brand name Caduet. Potential licensees would typically be generic pharmaceutical companies seeking to produce their own versions of the drug upon patent expiration or through licensing agreements.
What are the Key Generic Competitors?
Upon the expiration of the patent term and any associated market exclusivity, generic versions of amlodipine/atorvastatin combination products can enter the market. Key generic manufacturers in the cardiovascular space, such as Teva Pharmaceuticals, Mylan (now Viatris), Sun Pharmaceutical Industries, and Dr. Reddy's Laboratories, are likely to be active in this segment. The availability of bioequivalent generic alternatives significantly impacts pricing and market share.
Are there Other Patents Covering Similar Combinations?
Yes, pharmaceutical companies often file multiple patents covering different aspects of a drug, including different formulations, polymorphs, manufacturing processes, and therapeutic uses. It is common for a single branded drug to be covered by a portfolio of patents. For amlodipine/atorvastatin combinations, other patents might exist covering:
- Specific polymorphic forms of amlodipine besylate or atorvastatin calcium.
- Unique excipient combinations that improve stability or bioavailability.
- Novel manufacturing processes.
- Specific therapeutic regimens or patient populations.
A comprehensive patent landscape analysis would identify these related patents and their expiration dates to understand the full duration of market exclusivity. For example, patents covering the individual APIs (amlodipine and atorvastatin) have long since expired or would have expired independently. This patent specifically covers the combination in a particular formulation.
What is the Market Significance and Future Outlook?
The combination of amlodipine and atorvastatin addresses two major cardiovascular risk factors, hypertension and hyperlipidemia, making it a significant product in the cardiovascular market.
What is the Market Size for Amlodipine/Atorvastatin Combinations?
The market for amlodipine/atorvastatin fixed-dose combinations is substantial, driven by the high prevalence of cardiovascular diseases globally. While specific market size figures fluctuate and depend on regional data, the demand for effective treatments for hypertension and dyslipidemia remains consistently high. The introduction of generic versions after patent expiration typically leads to significant price reductions but an increase in overall volume and patient access.
What are the Implications of Patent Expiration for Market Dynamics?
The expiration of U.S. Patent 7,857,977, on May 26, 2024, has opened the door for generic competition. This typically results in:
- Price Erosion: Generic drugs are generally priced lower than branded equivalents, leading to significant cost savings for healthcare systems and patients.
- Increased Accessibility: Lower prices can increase patient access to treatment.
- Market Share Shift: Branded manufacturers typically experience a decline in market share as generic alternatives become widely available.
- Competition among Generic Manufacturers: The market becomes more competitive with multiple generic companies vying for market share, often leading to further price reductions.
Are There Any Emerging Trends or Future Considerations?
Future considerations for this therapeutic area include the development of novel drug delivery systems or next-generation combination therapies. While this specific patent covers a particular formulation, research continues into more convenient or effective ways to manage cardiovascular risk factors. This could include extended-release formulations, combination products with additional APIs (e.g., ACE inhibitors or diuretics), or therapies targeting different aspects of lipid metabolism or blood pressure regulation.
Key Takeaways
- U.S. Patent 7,857,977 protected pharmaceutical compositions containing amlodipine besylate and atorvastatin calcium as a fixed-dose combination.
- The patent claims focused on unitary dosage forms, specifically tablets, and methods for treating hyperlipidemia and hypertension.
- The patent's statutory term expired on May 26, 2024, making the protected technology now available for generic entry.
- Pfizer Inc. was the assignee of the patent, marketing the product as Caduet.
- The expiration of this patent has led to increased generic competition, driving down prices and increasing patient access to the combination therapy.
- A comprehensive understanding of the patent landscape, including related patents covering individual APIs and other formulations, is crucial for assessing market exclusivity.
Frequently Asked Questions
-
What specific strengths of amlodipine besylate and atorvastatin calcium are covered by the patent?
The patent covers specific amounts of amlodipine besylate (about 1 mg to about 10 mg) and atorvastatin calcium (about 5 mg to about 80 mg) within the claimed compositions.
-
Can generic manufacturers produce amlodipine/atorvastatin tablets that are not identical to Pfizer's Caduet formulation?
Yes, generic manufacturers can produce bioequivalent amlodipine/atorvastatin tablets that meet regulatory standards. However, they must ensure their formulations do not infringe on any other active patents covering aspects like novel excipients, manufacturing processes, or specific polymorphic forms that might still be in force.
-
What are the primary therapeutic benefits of combining amlodipine and atorvastatin?
The combination offers simultaneous treatment for hypertension (amlodipine) and hyperlipidemia (atorvastatin), addressing two major risk factors for cardiovascular disease in a single dosage form, improving patient compliance and convenience.
-
Are there any patents still in force that cover amlodipine or atorvastatin individually?
The primary patents covering the individual active pharmaceutical ingredients amlodipine and atorvastatin have long since expired. This patent specifically protects the fixed-dose combination.
-
What is a Paragraph IV certification in the context of this patent?
A Paragraph IV certification is a declaration made by a generic drug applicant to the U.S. Food and Drug Administration (FDA) stating that their proposed product does not infringe on a listed patent, or that the patent is invalid or unenforceable. This often triggers patent litigation, as the patent holder has 45 days to sue the generic applicant.
Citations
[1] Pfizer Inc. (2010). Pharmaceutical Compositions and Methods. U.S. Patent 7,857,977. Washington, D.C.: U.S. Patent and Trademark Office.
